Please Wait a Moment
X

News

See the latest updates and breaking news on how FHCP's work is making a difference in our key advocacy areas.

FHCP statement on FDA Proposal to End Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient

FHCP statement on FDA Proposal to End Use of Oral Phenylephrine as OTC Monograph Nasal Decongestant Active Ingredient

Author: Anthony Fuchs/November 11, 2024/Categories: Statement

(Ottawa) November 11, 2024 – FHCP and our members have monitored the U.S. Food and Drug Administration’s proposal to remove oral phenylephrine as an active ingredient in over-the-counter (OTC) monograph drug products. This is a proposed order and only a final order will affect what products can be marketed.

It is important to note that the FDA review of available data determined that oral phenylephrine is not effective for temporary relief of nasal congestion. In this proposed order, FDA confirmed that concerns with phenylephrine are based on effectiveness concerns, not on safety concerns.

In Canada, phenylephrine is approved for use as an oral decongestant. FHCP and our members will work with Health Canada to ensure self-care options continue to be readily available for Canadians during the upcoming cold and flu season.

Print

Number of views (524)/Comments (0)

 
 

About FHCP

Food, Health & Consumer Products of Canada (FHCP) is the voice of Canada’s leading food, health, & consumer product manufacturers. Our industry employs more people than any other manufacturing sector in Canada, across businesses of all sizes that manufacture and distribute the safe, high-quality products at the heart of healthy homes, healthy communities, and a healthy Canada.

Food, Health & Consumer Products of Canada
2700 Matheson Boulevard East, East Tower, Suite 602E
Mississauga, ON L4W 4V9
Tel: (416) 510-8024
Fax: (416) 510-8043

Follow Us